Literature DB >> 15700132

Views of patients with gynecologic cancer about the end of life.

Nezihe Kizilkaya Beji1, Nesrin Reis, Beyhan Bag.   

Abstract

This study was designed as a descriptive work assessing the reactions of gynecologic cancer patients to poor prognosis, determining their desires for the location of terminal care, and their preferences about life-sustaining technology. The study was carried out between 2002 and 2003 in a gynecologic oncology clinic of a university hospital located in Istanbul. Data were collected through interviews with 68 patients with gynecologic cancers. Collected data were analyzed through content analysis. It was found that survival is utterly important for the patients and that they wish to stay at hospitals as inpatients and receive life-sustaining treatments during the end-stage disease.

Entities:  

Mesh:

Year:  2005        PMID: 15700132     DOI: 10.1007/s00520-004-0747-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  18 in total

1.  JAMA patient page. Decisions about end-of-life care.

Authors: 
Journal:  JAMA       Date:  2000-11-15       Impact factor: 56.272

Review 2.  Medical futility and appropriate medical care in patients whose death is thought to be imminent.

Authors:  C P Escalante; C G Martin; L S Elting; E B Rubenstein
Journal:  Support Care Cancer       Date:  1997-07       Impact factor: 3.603

Review 3.  Special needs related to the pain and discomfort of patients with gynecologic cancer.

Authors:  C Miaskowski
Journal:  J Obstet Gynecol Neonatal Nurs       Date:  1996-02

4.  The oncology nurse's role in patient advance directives.

Authors:  E P Dimond
Journal:  Oncol Nurs Forum       Date:  1992-07       Impact factor: 2.172

5.  Home palliative care for terminal cancer patients: a survey on the final week of life.

Authors:  C Peruselli; P Di Giulio; F Toscani; M Gallucci; C Brunelli; M Costantini; M Tamburini; E Paci; G Miccinesi; J M Addington-Hall; I J Higginson
Journal:  Palliat Med       Date:  1999-05       Impact factor: 4.762

6.  Social and demographic characteristics of patients admitted to a palliative care unit.

Authors:  E Bruera; N Kuehn; B Emery; K Macmillan; J Hanson
Journal:  J Palliat Care       Date:  1990       Impact factor: 2.250

7.  The gynecologist and the dying cancer patient.

Authors:  D G Gallup; M Labudovich; P R Zambito
Journal:  Am J Obstet Gynecol       Date:  1982-09-15       Impact factor: 8.661

8.  How can relations be improved between the family and the support team during the care of terminally ill patients?

Authors:  W Astudillo; C Mendinueta; E Astudillo; A Muñoz; J P Horcajada
Journal:  Support Care Cancer       Date:  1995-01       Impact factor: 3.603

9.  Hard choices: the gynecologic cancer patient's end-of-life preferences.

Authors:  D Brown; J A Roberts; T E Elkins; D Larson; M Hopkins
Journal:  Gynecol Oncol       Date:  1994-12       Impact factor: 5.482

Review 10.  Ethical dilemmas in hospice and palliative care.

Authors:  B M Kinzbrunner
Journal:  Support Care Cancer       Date:  1995-01       Impact factor: 3.603

View more
  3 in total

1.  Caregivers needing care: the unmet needs of the family caregivers of end-of-life cancer patients.

Authors:  Maryam Hashemi; Alireza Irajpour; Fariba Taleghani
Journal:  Support Care Cancer       Date:  2017-09-27       Impact factor: 3.603

2.  'Palliative care': a contradiction in terms? A qualitative study of cancer patients with a Turkish or Moroccan background, their relatives and care providers.

Authors:  Fuusje M de Graaff; Anneke L Francke; Maria Etc van den Muijsenbergh; Sjaak van der Geest
Journal:  BMC Palliat Care       Date:  2010-09-10       Impact factor: 3.234

3.  Perspectives on care and communication involving incurably ill Turkish and Moroccan patients, relatives and professionals: a systematic literature review.

Authors:  Fuusje M de Graaff; Patriek Mistiaen; Walter Ljm Devillé; Anneke L Francke
Journal:  BMC Palliat Care       Date:  2012-09-18       Impact factor: 3.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.